124 results about "Atrophic mucosa" patented technology

The present invention provides a method and system for intelligent follow-up of chronic atrophic gastritis based on multi-source electronic medical records, which relates to the technical field of intelligent disease follow-up, including preprocessing and feature extraction of structured, semi-structured and unstructured electronic medical record data, mining the inter-layer feature association relationship by a meta-path reasoning module, and generating comprehensive graph features of patients; identifying the causal relationship between features by a Bayesian causal network module, and building a disease risk prediction model in combination with a temporal causal graph module; and optimizing the follow-up plan by a Nash equilibrium algorithm based on risk prediction results and medical resource constraints; the present invention can effectively predict the disease risk of chronic atrophic gastritis, and optimize the follow-up plan in combination with medical resources, thereby improving the follow-up efficiency and facilitating the early diagnosis and treatment of chronic atrophic gastritis.

The invention relates to the technical field of life science, in particular to a method for constructing an atrophic gastritis-based SPEM lesion model, which comprises the following steps: S1, constructing an Slc7a11 conditional knockout mouse strain: carrying out cage hybridization on an Slc7a11 flox / flox mouse and an ATP4b-Cre transgenic mouse, and knocking out a gastric wall cell specific Slc7a11 gene; s2, carrying out genotyping identification; the identification method based on the atrophic gastritis SPEM lesion model and the construction method based on the atrophic gastritis SPEM lesion model comprise the following steps: S1, pathological model verification: taking a mouse gastric mucosa tissue slice, quantitatively analyzing the proportion of an SPEM region by adopting an immunofluorescence double-standard technology, and confirming Slc7a11 knockout induced SPEM pathological characteristics in combination with the existence of SPEM in the gastric mucosa; and S2, long-term pathology evolution monitoring. Through gastric wall cell specific Slc7a11 gene knockout and multiple PCR identification technologies, the initial response SPEM state after gastric mucosa damage is successfully simulated, and the kit is used for researching atrophic gastritis pathological mechanisms and evaluating drug intervention.

The invention relates to the technical field of small molecule medicines, in particular to a medicine for improving chronic atrophic gastritis and application of the medicine. The invention aims to provide a compound, a pharmaceutical composition containing the compound and application of the compound, the 9, 13-substituted berberine derivative has a good improvement effect on CAG, and further research and observation of the compound on treatment of CAG gastric mucosa gland epithelial cell atrophy, gastric mucosa thinning, gastric mucosa epithelial cell atrophy, gastric mucosa hyperplasia, gastric mucosa epithelial cell atrophy and gastric mucosa hyperplasia. The 9, 13-substituted berberine derivative disclosed by the invention can be used for preventing and / or treating CAG (chorionic gonadotrophin) by virtue of the inhibition effects on infiltration adhesion of a large number of neutrophils and lymphocytes, inflammatory factors and the like.

A lamb stomach extract Vitamin B12 preparation composition composed of lamb stomach extract and Vitamin B12 is provided. The lamb stomach extract has a chymosin activity of >40 U / g and a pepsin activity of >15 U / g, and the weight ratio of the lamb stomach extract and Vitamin B12 is 100000:0.5-5, which is useful in the treatment of moderate-to-severe chronic atrophic gastritis, intestinal metaplasia reversal, and gastric cancer prevention. Lamb stomach extract and Vitamin B12 produced synergistic or synergistic effects in specific ratios.

The invention discloses a pharmaceutical composition for preventing and treating chronic atrophic gastritis. The pharmaceutical composition is prepared from the following raw materials in the following weight ratio: 14-18 parts of peach kernel, 10-14 parts of Chuanxiong rhizome, 8-12 parts of Panax notoginseng, 6-10 parts of safflower, 20-28 parts of kelp, 10-14 parts of selfheal, 15-25 parts of codonopsis pilosula, 10-14 parts of atractylodes macrocephala, 12-16 parts of fructus aurantii, 8-12 parts of amomum villosum, 12-16 parts of bupleurum, 10-18 parts of citron, and 5-10 parts of fucoidan. The pharmaceutical composition is used to treat chronic atrophic gastritis of gastric collateral blood stasis type by promoting blood circulation and removing blood stasis, unblocking meridians and relieving pain, eliminating phlegm, softening and dispersing nodules, invigorating qi and promoting qi circulation, and soothing the liver and harmonizing the stomach. The invention also discloses a preparation method of the pharmaceutical composition.

The invention belongs to the technical field of experimental zoology, and particularly relates to a gastric cancer precancerous lesion animal model and a construction method and application thereof. The construction method of the gastric precancerous lesion animal model comprises the following steps that a modeling animal freely drinks a modeling agent solution every day for modeling, and the concentration of the modeling agent solution is increased in a gradient mode within 200 mg / L-800 mg / L along with the modeling time. The gastric cancer precancerous lesion animal model is constructed by the method. The gastric precancerous lesion animal model is applied to screening, research and development of traditional Chinese medicines for treating gastric precancerous lesions including chronic atrophic gastritis, intestinal metaplasia and dysplasia. The method can solve the technical problem that the existing gastric precancerous lesion animal model construction method cannot accurately simulate the disease stage evolution, can simply, conveniently and efficiently construct the gastric precancerous lesion model, and has important meanings for scientific research verification, drug research and development, quality control, clinical application and the like of traditional Chinese medicines or formulae for treating gastric precancerous lesions.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method and application thereof. According to the technical scheme, the traditional Chinese medicine composition is characterized by being prepared from, by weight, 10-50 parts of radix codonopsis, 5-20 parts of roasted rhizoma atractylodis macrocephalae, 5-10 parts of rhizoma pinellinae praeparata, 2-8 parts of rhizoma coptidis, 8-40 parts of poria cocos, 5-15 parts of radix salviae miltiorrhizae, 3-6 parts of rhizoma zingiberis, 5-15 parts of rhizoma cyperi, 1-20 parts of radix actinidiae chinensis and 1-5 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition provided by the invention can improve the pathological morphology of stomach tissues, increase the expression of PG I and the ratio of PG I to PG II, reduce the level of inflammatory factors and improve the atrophy degree of gastric mucosa, and is used for treating stomachache, distention and fullness, anorexia, gastric noisy and other symptoms caused by spleen and stomach qi deficiency, qi stagnation and blood stasis and damp-toxin interjunction of patients with chronic atrophic gastritis.

The invention provides a non-classical ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound with a good inhibition effect on ferroptosis, the compound can be used for preparing a ferroptosis inhibitor, and the structure of the compound is shown as a formula I in the specification. The compound can be used for preparing medicines for preventing and / or treating ferroptosis-related neurodegenerative diseases, tissue ischemia-reperfusion injury, cerebral apoplexy, cardiovascular diseases, renal failure, inflammation, cardiotoxicity, acute organ injury, chronic atrophic gastritis or diabetic complications and other diseases, and has a wide market prospect. # imgabs0 #

The invention relates to a Chinese medicine composition, and discloses a medicine composition for treating chronic atrophic gastritis, a preparation method thereof and a use thereof. The medicine composition is prepared from effective ingredients and pharmaceutically acceptable auxiliary materials, wherein the effective ingredients are prepared from raw materials in the following weight ratio: 4-8g of red ginseng, 12-18g of white atractylodes, 4-8g of notoginseng, 4-6g of angelica, 8-12g of curcuma, 12-18g of coix seed, 12-18g of fritillaria thunbergii, 8-12g of dendrobium, 12-18g of falanghai, and 8-12g of salacia. Red ginseng and notoginseng are extracted by ethanol refluxing to obtain red ginseng and notoginseng extracts; red ginseng, notoginseng residues and the remaining eight raw materials are boiled and extracted with water, and the filtrate is concentrated and then added with the red ginseng and notoginseng extracts to prepare the preparation. This combination warms the spleen and replenishes qi, removes dampness and resolves blood stasis. It is used for chronic atrophic gastritis caused by spleen and stomach yang deficiency, internal obstruction of dampness and blood stasis, or accompanied by intestinal metaplasia and intraepithelial neoplasia. Symptoms include fullness in the epigastric region, noisy or dull pain in the stomach, decreased appetite, etc. It has a significant therapeutic effect on spleen and stomach yang deficiency, internal obstruction of dampness and blood stasis, etc.

The present invention provides a Chinese medicine composition and extract and application for treating chronic atrophic gastritis. A Chinese medicine composition for treating chronic atrophic gastritis comprises the following Chinese medicinal materials in weight proportion: 12-18g of Blumea Balsamifera, 15-25g of Radix Achyranthis Bidentatae, 15-25g of Rhizoma Cibotii, 8-12g of Agastache rugosa, 8-12g of Alpinia officinalis, 2-4g of Panax notoginseng, and 2-4g of Aquilaria sinensis. Compared with the existing Chinese medicine formula, the Chinese medicine formula of the present invention treats chronic atrophic gastritis, and the symptom relief of the patient is very obvious, and the degree of atrophy and functional state of the patient's gastric mucosa are better improved, and the quality of life of patients with chronic atrophic gastritis can be better improved. It has a wide range of application and can be applied to patients with chronic atrophic gastritis of different constitutions or syndromes.

The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of radix codonopsis, 10 to 20 parts of rhizoma atractylodis macrocephalae, 10 to 15 parts of poria cocos, 10 to 12 parts of pericarpium citri reticulatae, 6 to 10 parts of rhizoma pinellinae praeparata, 10 to 12 parts of radix aucklandiae, 10 to 12 parts of rhizoma corydalis, 3 to 6 parts of radix notoginseng, 10 to 12 parts of fructus aurantii immaturus, 10 to 20 parts of radix ginseng rubra, 15 to 30 parts of herba hedyotidis diffusae, 15 to 30 parts of semen coicis, 10 to 15 parts of rhizoma curcumae, 10 to 20 parts of radix salviae miltiorrhizae, 10 to 20 parts of radix astragali seu hedysari and 3 to 6 parts of liquorice root. The invention further discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition aims at chronic atrophic gastritis with pathological characteristics of gastric mucosa dysplasia and intestinal metaplasia, and is remarkable in curative effect and small in side effect through reasonable medicine compatibility.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method of the traditional Chinese medicine composition. Comprising the following raw materials: 2-30 parts of astragalus membranaceus, 2-30 parts of bighead atractylodes rhizome, 1-30 parts of codonopsis pilosula, 1-30 parts of poria cocos, 1-30 parts of Chinese yam, 1-40 parts of salvia miltiorrhiza, 2-30 parts of rhizoma sparganii, 1-40 parts of curcuma zedoary, 1-20 parts of elecampane, 1-20 parts of fructus amomi, 2-30 parts of pericarpium citri reticulatae, 1-30 parts of rhizoma pinellinae praeparata, 1-30 parts of dried ginger, 5-20 parts of coptis chinensis, 1-30 parts of immature bitter orange, 3-30 parts of endothelium corneum gigeriae galli and 2-30 parts of raw liquorice. The traditional Chinese medicine composition disclosed by the invention can be used for effectively treating clinical symptoms of CAG, reversing atrophy, intestinal metaplasia and dysplasia of mucosa, remarkably improving endoscopic manifestation of a CAG patient and promoting lesion of gastric mucosa to be relieved or disappear. Animal experiments show that the traditional Chinese medicine can reduce and reverse lesions such as gastric mucosa gland atrophy and epithelium intestinal metaplasia of CAG rats. Mitochondrial metabolic disorder is a key link of CAG gland atrophy and can effectively block CAG canceration.

The invention belongs to the technical field of medical image automatic identification, and particularly relates to an atrophic gastritis automatic identification system based on a generative adversarial network, which comprises a data acquisition module used for acquiring a gastroscope image of a required part, and marking the part of the gastroscope image, the atrophy condition and the atrophy area information to obtain a gastroscope image data set; the double sampling module is used for carrying out preprocessing and double sampling on the gastroscope image data set to obtain a balanced gastroscope image data set; the model training module is used for respectively training a Murmuraea bamboo typing model and an atrophy area identification model by utilizing the balanced gastroscope image data set; the combined recognition module is used for processing the gastroscope image to be detected by utilizing the Murmun bamboo typing model and the atrophic area recognition model, carrying out combined recognition and determining the severity of the atrophic gastritis in the gastroscope image; according to the method, automatic identification of atrophic gastritis can be carried out on the gastroscope image, and the method has high accuracy to assist doctors.

The present invention belongs to the technical field of automatic recognition of medical images, and particularly relates to an automatic recognition system for atrophic gastritis based on a generative adversarial network, including a data acquisition module for acquiring gastroscope images of the required part and annotating the part, whether there is atrophy and atrophy region information of the gastroscope images to obtain a gastroscope image data set; a dual sampling module for preprocessing and dual sampling the gastroscope image data set to obtain a balanced gastroscope image data set; a model training module for using the balanced gastroscope image data set to train a Kimura-Takemoto classification model and an atrophy region recognition model respectively; and a joint recognition module for using the Kimura-Takemoto classification model and the atrophy region recognition model to process the to-be-tested gastroscope image respectively for joint recognition to determine the severity of atrophic gastritis in the gastroscope image. The present invention can automatically recognize atrophic gastritis in gastroscope images with high accuracy to assist doctors.

The utility model relates to the technical field of medical apparatus and instruments, in particular to a detection sampling device for atrophic gastritis, which comprises a sleeve and a sampling component, an arc-shaped plate is connected to the outer side of the sleeve in a hot melting manner, a metal hose is fixedly connected to the bottom of the arc-shaped plate through a bolt, a connecting rod is sleeved at the top end of the sleeve, and the sampling component is connected with the connecting rod. A steel wire is fixed at the bottom end of the connecting rod through a bolt; a sampling assembly is arranged at one end of the metal hose and comprises an arc-shaped umbrella cover welded to one end of the steel wire and a column sleeve welded to one end of the metal hose, and grooves are formed in the outer side of the column sleeve at equal intervals; after the sampling assembly is inserted into the stomach of a patient, the rotating column sleeve makes contact with the interior of the stomach, so that gastric mucosa fluid makes contact with and adheres to the interior of the groove, the gastric mucosa fluid is sampled, the arc-shaped umbrella cover is pulled through the steel wire, the arc-shaped umbrella cover moves to scrape gastric mucosa tissue, and the gastric mucosa tissue is sampled.

The invention discloses a new application of Renqingchangjue and an extract of Renqingchangjue. Specifically, the invention provides a new application of Tibetan medicine Renqingchangjue and an extract in preparation of a medicine for treating chronic atrophic gastritis, and systematically clarifies an exact molecular mechanism of the Tibetan medicine Renqingchangjue for treating CAG. The core of the invention is to reveal the core signal axis of Renqingchangjue by inhibiting TNF / NF-kB / Caspase-3 for the first time, so that the Renqingchangjue synergistically exerts the effects of resisting inflammation, resisting apoptosis and promoting mucosa repair, and provides a new intervention target and scientific basis for reversing gastric mucosa gland atrophy. The invention not only provides a modern pharmacological basis for the clinical curative effect of the Renqingchangjue, but also provides a brand new technical scheme and a protection basis for developing a medicine or a medicine composition which is based on the clear pathway target and is used for treating the chronic atrophic gastritis.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition with the function of relieving stomach inflammation and a preparation method and application. The traditional Chinese medicine composition comprises a main medicine and an auxiliary medicine, the main medicine consists of cuttle bone, thunberg fritillary bulb and rheum officinale; the adjuvants comprise a first adjuvant and a second adjuvant; the first adjuvant is belladonna and daphniphyllum calycinum; the second adjuvant comprises fructus aurantii and cortex magnoliae officinalis. The traditional Chinese medicine composition provided by the invention is simple in component, only a trace amount of belladonna extract needs to be added, meanwhile, daphniphyllum calycinum is compounded, the addition of excessive other unnecessary components is avoided, and the symptom of chronic non-atrophic gastritis with erosion can be remarkably improved.

The invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 280-320 parts of red ginseng; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 580 to 620 parts of rhizoma atractylodis macrocephalae, 280 to 320 parts of rhizoma zingiberis, 80 to 120 parts of sandalwood, 280 to 320 parts of edible tulip, 580 to 620 parts of concha arcae, 580 to 620 parts of oldenlandia diffusa, 180 to 220 parts of notholirion bulbuliferum and 280 to 320 parts of sea buckthron oil. The total effective rate of the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia is 93%, and the traditional Chinese medicine composition has a remarkable clinical effect on treating chronic atrophic gastritis with intestinal metaplasia clinically.

The composition provided by the invention takes bear gall wood as a monarch drug and takes earthworm, bletilla striata, bighead atractylodes rhizome, Chinese yam and white paeony root as ministerial drugs, the earthworm and bletilla striata jointly play the effects of promoting blood circulation to remove meridian obstruction, dispersing blood stasis, removing stasis, astringing to stop bleeding and repairing injury, and the bighead atractylodes rhizome and Chinese yam are used as ministerial drugs and are used for strengthening spleen and stomach, replenishing qi and blood, providing fundamental power for the whole prescription and supporting healthy qi; liver softening, spasm relieving and pain relieving can be achieved; meanwhile, the traditional Chinese medicine composition has the effects of nourishing blood and astringing yin, can prevent other medicines in the formula from being too warm and dry or consuming yin blood, and forms dynamic and static combination compatibility with the minister medicine earthworm for promoting blood circulation to remove meridian obstruction; hairyvein agrimony, herba violae, vernonia graveolens, cuttlebone, mangnolia officinalis, semen raphani and endothelium corneum gigeriae A large number of pathological experiments prove that the traditional Chinese medicine composition can reduce stomach tissue inflammation, oxidative stress and activate apoptosis signal channels by acting on MAPK, PI3K-Akt and HIF-1 signals, so that the effect of treating chronic atrophic gastritis is achieved.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

This invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for treating chronic atrophic gastritis provided by this invention is made from the following raw materials in parts by weight: 15-25 parts of Salvia miltiorrhiza, 8-16 parts of Curcuma zedoaria (processed with vinegar), 2-6 parts of Eupolyphaga sinensis, 10-20 parts of Codonopsis pilosula, 8-16 parts of Dendrobium nobile (dried), 5-15 parts of Pinellia ternata (processed), 1-5 parts of Evodia rutaecarpa (processed), and 1-5 parts of Coptis chinensis. It has the effects of promoting blood circulation and removing blood stasis, strengthening the spleen and replenishing qi, nourishing yin and benefiting the stomach, inhibiting bacteria and inflammation, and regulating immunity. It is suitable for chronic atrophic gastritis, especially those with gastric blood stasis combined with stomach yin deficiency or spleen and stomach weakness. It can significantly repair the gastric mucosa and reverse atrophic intestinal metaplasia, and is safe and reliable, providing a new traditional Chinese medicine treatment for chronic atrophic gastritis.

The invention discloses a traditional Chinese medicine formula for treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition comprises the following components in parts by weight: 16-20 parts of Zhejiang radix ophiopogonis, 15-20 parts of moutan bark, 28-32 parts of salvia miltiorrhiza, 10-14 parts of pseudo-ginseng slices, 15-18 parts of curcuma zedoary, 18-22 parts of codonopsis pilosula, 28-32 parts of astragalus membranaceus and 28-32 parts of oldenlandia diffusa. The preparation method comprises the following steps: (1) cleaning the medicinal materials, and then cutting into small blocks to obtain a mixed medicinal material; (3) boiling with big fire after soaking, continuing to decoct with small fire, and filtering to obtain first medicine liquid and medicine residues; and (4) adding water again, boiling with big fire, continuously decocting with small fire, filtering to obtain a second liquid medicine, and mixing the first liquid medicine and the second liquid medicine. The traditional Chinese medicine composition can obviously improve inflammation and atrophic lesion of gastric mucosa, and has a remarkable effect on treating atrophic gastritis with intestinal metaplasia and atypical hyperplasia.

The present application belongs to the technical field of bioinformatics, and specifically relates to a chronic atrophic gastritis biomarker screening method and system based on a multi-modal differential network. The present application comprises: preprocessing metabolome data and microbiome data, respectively constructing intra-modal interaction graphs and inter-modal interaction graphs, and obtaining a multi-modal differential network by making a difference between the interaction graphs under different clinical groupings; based on the constructed differential network, a multi-level difference evaluation index is constructed: CDI is calculated at the node level to quantify the network topology and biological function differences of the biomarkers; at the structure level, a group specificity index GSI is defined to characterize the group specificity of the differential network structure; the feature ranking results obtained by CDI and GSI are fused and screened to obtain a biomarker set for atrophic gastritis classification prediction. The present application improves the effectiveness of biomarker screening under the condition of small sample and high dimension, and provides support for subsequent targeted cultivation of candidate colonies and metabolites and development of potential intervention target points.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. Comprising the following raw materials in parts by weight: 25-35 parts of honey-fried astragalus membranaceus, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 8-10 parts of ginseng, 5-8 parts of elecampane, 2-4 parts of fructus amomi, 12-18 parts of codonopsis pilosula, 12-18 parts of poria cocos, 8-10 parts of vinegar-processed curcuma zedoary, 2-4 parts of pseudo-ginseng, 8-12 parts of oldenlandia diffusa, 10-15 parts of medlar, 8-10 parts of pericarpium citri reticulatae, 5-7 parts of ginger processed pinellia, 0.08-0.12 part of naringin and 5-7 parts of liquorice. The traditional Chinese medicine composition disclosed by the invention takes spleen invigorating and qi supplementing, qi regulating and blood activating, precise regulation and control and mucous membrane repairing as the core, specifically solves the pathogenesis of spleen deficiency and qi stagnation type CAG with deficiency in root and excess in excess, inhibits the progression of precancerous lesions, and improves the treatment effectiveness and safety.

The embodiment of the invention discloses a pharmaceutical composition for inhibiting and delaying inflammatory-cancerous transformation of atrophic gastritis as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises the following components in parts by weight: 3-30 parts of coptis chinensis and 1-10 parts of fructus evodiae. In-vivo experiments prove that the pharmaceutical composition can improve related objective indexes such as gastric mucosa epithelial cell proliferation, rat serum inflammatory factors and lipid metabolism key enzymes of CAG model rats, can repair damaged gastric mucosa inherent glands, prevents and prolongs intestinal metaplasia and atypical hyperplasia, and has the effects of preventing and treating intestinal metaplasia and hyperplasia. The traditional Chinese medicine composition has good prevention and treatment effects on atrophic gastritis and gastric precancerous lesions.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, a pharmaceutical preparation and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 5 to 18 parts of rhizoma coptidis, 5 to 18 parts of rhizoma zingiberis, 4 to 15 parts of radix scutellariae, 5 to 18 parts of rhizoma pinelliae, 9 to 27 parts of radix astragali seu hedysari, 5 to 18 parts of radix codonopsis, 5 to 18 parts of rhizoma atractylodis macrocephalae, 5 to 18 parts of herba dendrobii, 5 to 18 parts of radix curcumae, 5 to 18 parts of radix salviae miltiorrhizae, 5 to 18 parts of rhizoma curcumae, 10 to 30 parts of herba hedyotidis diffusae and 5 to 18 parts of fructus aurantii immaturus. The traditional Chinese medicine composition provided by the invention can effectively block, slow down and reverse the chronic atrophic gastritis with intestinal metaplasia'inflammation-cancer transformation 'process, and is low in cost, small in side effect and high in patient compliance.

The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and gastric precancerous lesions, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 8-15 parts of ginseng, 15-45 parts of quinquefolius, 10-30 parts of acanthopanax senticosus, 5-15 parts of fructus aurantii, 10-30 parts of trigonosciadium japonicum, 10-20 parts of zedoaria, 5-15 parts of parsley, 3-6 parts of scorpion, 3-5 parts of centipede, 10-30 parts of smilax china and 5-15 parts of roasted liquorice. The traditional Chinese medicine composition of the present invention uses ginseng, Acanthopanax senticosus and Tripterygium wilfordii as main medicines, uses Eleutherodactyla quinquefolia, Curcuma zedoaria, Paris polyphylla, Rhizoma scutellariae, Scorpio and Scolopendra subspinipes as assistant medicines, uses Fructus aurantii and Radix Glycyrrhizae Radix et Rhizoma as adjuvant medicines, and can improve the general state, body weight, gastric mucosal lesions, gastric digestive function, and expression of gastric "inflammation-cancer" transformation markers of mice with chronic atrophic gastritis and gastric precancerous lesions models, has significant therapeutic effects on chronic atrophic gastritis and gastric precancerous lesions, and has no liver and kidney toxicity.

This invention belongs to the field of gastric disease treatment, specifically relating to a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and its preparation method. The traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia comprises the following raw materials in parts by weight: Agrimonia pilosa 10-15 parts, Cyperus rotundus 8-10 parts, Scutellaria barbata 10-15 parts, Lobelia chinensis 10-15 parts, Patrinia scabiosaefolia 13-17 parts, Scutellaria baicalensis 7-11 parts, Hedyotis diffusa 10-15 parts, Prunella vulgaris 10-15 parts, Hedyotis diffusa 5-7 parts, Perilla frutescens 8-10 parts, Coptis chinensis 5-7 parts, Angelica sinensis 5-7 parts, etc. This invention focuses on the core pathogenesis of damp-heat in the spleen and stomach and stagnation of gastric collaterals. The Chinese herbal composition has the effects of clearing heat and removing dampness, regulating qi and harmonizing the stomach, nourishing blood and unblocking collaterals. Clinically, it can significantly improve the OLGA / OLGIM stage of patients with chronic atrophic gastritis with intestinal metaplasia, with a total effective rate of 65.1%, providing a safe and effective Chinese medicine solution for precancerous lesions of the stomach.

The invention relates to the field of epigastric pain treatment, in particular to a repairing medicament for treating epigastric pain atrophic gastritis with erosion and intestinal metaplasia. Comprising the following components in parts by weight: 10-20 parts of radix bupleuri, 10-20 parts of radix paeoniae alba, 10-20 parts of fructus aurantii immaturus, 8-12 parts of raw liquorice, 10-20 parts of rhizoma atractylodis macrocephalae, 10-20 parts of poria cocos, 10-20 parts of radix pseudostellariae, 10-20 parts of radix angelicae sinensis, 10-20 parts of ligusticum wallichii, 10-20 parts of radix rehmanniae preparata, 10-20 parts of radix aucklandiae, 10-20 parts of pawpaw, 10-20 parts of fructus aurantii, 10-20 parts of radix linderae, 20-40 parts of lily, 15-25 parts of rhizoma corydalis, 15-25 parts of radix salviae miltiorrhizae, 15-25 parts of dandelion, 15-25 parts of white flower herb, 10-20 parts of rhizoma bletillae and 10-20 parts of radix notoginseng. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 20-40 parts of cuttlebone, 20-40 parts of corrugated shells, 15-25 parts of curcuma zedoary, 20-40 parts of endothelium corneum gigeriae galli, 15-25 parts of thunberg fritillary bulb, 15-25 parts of oyster, 10-20 parts of coptis chinensis and 15-20 parts of serissa serissoide. The radix bupleuri and the fructus aurantii immaturus are used for soothing the liver and regulating qi, the rhizoma atractylodis macrocephalae and the poria cocos are matched for strengthening the spleen and eliminating dampness, and improving qi stagnation of the spleen and the stomach, and a plurality of dosage forms are adopted in the preparation mode, so that decoction, oral thick paste, powder, pills and tablets can be provided to meet the requirements of different patients.